该研究尚未获得伦理委员会批准。请于批准后才开始纳入参试者,并与我们联系上传批件。 基于深度神经网络的盆腔淋巴结自动识别系统的前瞻性临床研究

注册号:

Registration number:

ChiCTR1900023255 

最近更新日期:

Date of Last Refreshed on:

2019-05-18 22:53:54 

注册时间:

Date of Registration:

2019-05-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

该研究尚未获得伦理委员会批准。请于批准后才开始纳入参试者,并与我们联系上传批件。 基于深度神经网络的盆腔淋巴结自动识别系统的前瞻性临床研究

Public title:

Prospective Clinical Study for Pelvic Lymph Node Automatic Recognition System Based on Deep Neural Network

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于深度神经网络的盆腔淋巴结自动识别系统的前瞻性临床研究

Scientific title:

Prospective Clinical Study for Pelvic Lymph Node Automatic Recognition System Based on Deep Neural Network

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

卢嘉琦 

研究负责人:

卢云 

Applicant:

Lu Jiaqi 

Study leader:

Lu Yun 

申请注册联系人电话:

Applicant telephone:

+86 17854239802

研究负责人电话:

Study leader's
telephone:

+86 18661802231

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

987321728@qq.com

研究负责人电子邮件:

Study leader's E-mail:

cloudylucn@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国山东青岛市经济技术开发区五台山路1677号

研究负责人通讯地址:

中国山东青岛市经济技术开发区五台山路1677号

Applicant address:

1677 Wutaishan Road, Economic and Technological Development Zone, Qingdao, Shandong, China

Study leader's address:

1677 Wutaishan Road, Economic and Technological Development Zone, Qingdao, Shandong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

青岛大学附属医院

Applicant's institution:

Affiliated Hospital of Qingdao University

研究负责人所在单位:

青岛大学附属医院

Affiliation of the Leader:

Affiliated Hospital of Qingdao University

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

青岛大学附属医院

Primary sponsor:

Affiliated Hospital of Qingdao University

研究实施负责(组长)单位地址:

中国山东青岛市经济技术开发区五台山路1677号

Primary sponsor's address:

1677 Wutaishan Road, Economic and Technological Development Zone, Qingdao, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

青岛

Country:

China

Province:

Shandong

City:

Qingdao

单位(医院):

青岛大学附属医院

具体地址:

经济技术开发区五台山路1677号

Institution
hospital:

Affiliated Hospital of Qingdao University

Address:

1677 Wutaishan Road, Economic and Technological Development Zone

经费或物资来源:

青岛大学数字医学与计算机辅助手术研究院

Source(s) of funding:

Institute of Digital Medicine and Computer Aided Surgery, Qingdao University

研究疾病:

直肠癌  

Target disease:

rectal cancer

研究疾病代码:

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

通过直肠癌病人术后病理结果、临床预后情况、生存质量等方面。比较传统的医生诊疗方式与基于深度神经网络的盆腔淋巴结自动识别系统评估结果,着重比较两者病理金标准的诊断差异;对治疗方式干预后的预后差异;对患者生存情况的影响等。明确基于深度神经网络的盆腔淋巴结自动识别系统的临床应用价值。  

Objectives of Study:

Through the postoperative pathological results, clinical prognosis and quality of life of rectal cancer patients. Comparing the evaluation results of the traditional doctor diagnosis and treatment method and the pelvic lymph node automatic identification system based on the deep neural network, and emphatically comparing the diagnostic differences of the two pathological gold standards; The difference of prognosis after intervention of treatment methods; The impact on the survival of patients, etc. To clarify the clinical application value of pelvic lymph node automatic identification system based on deep neural network.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.合并糖尿病、风湿免疫性疾病、严重的心脑肾等系统性疾病
2.影像证实存在盆腔器官异性
3.行盆腔其他手术

Exclusion criteria:

1. Combined with diabetes, rheumatic immune diseases, serious heart, brain, kidney and other systemic diseases
2. Imaging confirmed pelvic organ anisotropy
3. Been conducted other pelvic surgery

研究实施时间:

Study execute time:

From 2019-09-01 00:00:00 To 2021-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-09-01 00:00:00 To 2020-03-31 00:00:00

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

术后病理结果

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Postoperative pathological results

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

1.人工智能影像诊断; 2.传统影像诊断

Index test:

1.Artificial intelligence diagnostic image; 2.Traditional image diagnosis

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

直肠癌患者

例数:

Sample size:

60

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Rectal cancer patients

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

青岛 

Country:

China

Province:

Shandong

City:

Qingdao

单位(医院):

青岛大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

Affiliated Hospital of Qingdao University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

术后病理结果

指标类型:

主要指标

Outcome:

Postoperative pathological results

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗后生活质量

指标类型:

次要指标

Outcome:

Quality of life after treatment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床预后

指标类型:

次要指标

Outcome:

Clinical prognosis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生存期

指标类型:

次要指标

Outcome:

lifetime

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SEN, SPE, ACC, AUC of ROC

指标类型:

主要指标

Outcome:

SEN, SPE, ACC, AUC of ROC

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 40 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

N/A

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2022-03-01 Resman www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2022-03-01 Resman www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture, EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2019-05-18 22:25:04